People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

8:34pm IST
Change (% chg)

$0.04 (+0.11%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lundberg, Sven 

Dr. Sven Ante (Bill) Lundberg, M.D., has been Chief Scientific Officer of CRISPR Therapeutics Ltd since February 2015. Prior to that, he was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc., or Alexion, a biopharmaceutical company, from March 2011 to January 2015. From March 2010 to January 2011, he was Chief Medical Officer at Taligen Therapeutics, Inc., a biotechnology company that was acquired by Alexion in January 2011, and Vice President of Clinical Development at Antisoma Plc, or Antisoma, from May 2008 to March 2010. he also served as Vice President of Clinical Development at Xanthus Pharmaceuticals, Inc. from 2004 until it was acquired by Antisoma in 2008. Previous to that, he served as the Medical Director at Wyeth (acquired by Pfizer Inc. in January 2009) and Medical Director at Genzyme Corporation. He received an M.D. from Stanford University School of Medicine, an MBA from the Isenberg School of Management at the University of Massachusetts – Amherst, and a B.S. in Biology from the Massachusetts Institute of Technology, or MIT. He completed post-doctoral work at the Whitehead Institute for Biomedical Research at MIT.

Basic Compensation

Total Annual Compensation, USD 431,889
Restricted Stock Award, USD 1,760,400
Long-Term Incentive Plans, USD --
All Other, USD 383,513
Fiscal Year Total, USD 2,575,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --